SENIOR LEADERSHIP

7.1 Winship癌症研究所的高级领导 温希普癌症研究所所长兼 伍德拉夫健康科学中心：布赖恩Leyland-Jones，医学博士，博士 博士Leyland-Jones被任命为埃默里大学Winship癌症研究所（WCI）主任， 伍德拉夫健康科学中心（WHSC）副主任，2007年1月1日生效。 他非常有资格担任WCI主任。一位专门从事 乳腺癌治疗，博士学位在分子药理学方面，Leyland-Jones博士是一位 翻译医生，科学家谁是国际公认的工作，在个性化 癌症治疗和开发新的临床试验。在任命之前，莱兰博士- 琼斯是Minda de Gunzberg肿瘤学主席和麦吉尔大学医学教授 加拿大蒙特利尔大学。从1990年到2000年，他担任肿瘤学的创始主席 兼麦吉尔大学综合癌症中心主任。1983-89年，他 研究药物分支研发化疗科负责人， 癌症治疗，在国家癌症研究所。 博士Leyland-Jones领导Winship癌症研究所的能力是 通过他以前的高级职位和作为首席翻译的经验， 科学家在担任麦吉尔综合癌症中心主任期间， Leyland-Jones领导了一项临床试验操作的开发， 临床试验合作组和40多家制药公司。在Dr. 在Leyland-Jones的指导下，麦吉尔大学的癌症相关临床试验包括100多个 协议在任何一个时间，并通过九个多学科疾病部分的结构 在整个癌症中心。在NCI工作期间，他负责 开发了大约70种处于不同过渡阶段的抗癌化合物， 体外筛选至III期临床试验。他在肿瘤临床药物遗传学方面的专长 I/II期抗癌药物的临床试验和生物标志物终点强调了他高超的 领导WCI及其科学计划的背景，并在这方面共享核心资源 NCI被指定为癌症中心。 Leyland-Jones博士在担任Winship癌症研究所所长期间，提供了全面的 WCI的领导，其科学计划，其共享的核心资源，其组织， 局Leyland-Jones博士在战略规划和领导方面代表WCI 伍德拉夫健康科学中心和医学院的委员会 主席理事会。署长的权力在《 上一节。Leyland-Jones博士控制着空间，设施，筹款的分配， 预算和Winship癌症研究所的其他资源。与个别部门联合 主席，他有能力招募新的教师到埃默里大学，并与会员 他负责监督WCI的会员资格。作为矩阵中心的主任，莱兰博士- 琼斯与医学院的其他院长和系主任密切互动， 在伍德拉夫健康科学中心和埃默里学院的护理和公共卫生。他 也代表WCI与我们的社区合作伙伴合作，包括美国 癌症协会、CDC、格鲁吉亚癌症联盟、格鲁吉亚研究联盟、格鲁吉亚研究所 技术，莫尔豪斯医学院，GA-CORE和其他机构在整个 格鲁吉亚。Leyland-Jones博士提供了与国家癌症研究所的接口， 国家和地方媒体以及患者倡导组织和基金会。 博士Leyland-Jones致力于全职担任WCI董事和校长 他是CCSG的调查员，但只有25%的工作得到CCSG预算的支持。他将 提供高级领导、监督、战略规划和持续进展评估 在项目期间实现既定的目标和目的。

7.1 Senior Leadership of the Winship Cancer Institute Director of the Winship Cancer Institute and Associate Vice-President for the Woodruff Health Sciences Center: Brian Leyland-Jones, MD, PhD Dr. Leyland-Jones was appointed Director of Emory's Winship Cancer Institute (WCI) and Associate Director of the Woodruff Health Sciences Center (WHSC) effective January 1, 2007. He is eminently well-qualified to serve as WCI Director. A Medical Oncologist who specializes in breast cancer treatment, with a Ph.D. in Molecular Pharmacology, Dr. Leyland-Jones is a translational physician-scientist who is internationally recognized for his work in individualized cancer therapies and development of novel clinical trials. Prior to his appointment, Dr. Leyland- Jones was the Minda de Gunzberg Chair in Oncology and Professor of Medicine at McGill University in Montreal, Canada. From 1990 to 2000, he served as founding Chair of Oncology and Director of the McGill University Comprehensive Cancer Centre. From 1983-89 he was Head, Developmental Chemotherapy Section in the Investigational Drug Branch, Division of Cancer Treatment, at the National Cancer Institute. Dr. Leyland-Jones' capacity to lead the efforts at the Winship Cancer Institute is demonstrated through his prior senior positions and experiences as a premier translational scientist. During his tenure as Director of the McGill Comprehensive Cancer Centre, Dr. Leyland-Jones led development of a clinical trials operation that integrated research with five clinical trial cooperative groups and more than 40 pharmaceutical companies. Under Dr. Leyland-Jones' direction, cancer-related clinical trials at McGill included more than 100 protocols at any one time and were structured through nine multidisciplinary disease sections throughout the Cancer Centre. During his time with the NCI, he was responsible for the overall development of approximately 70 anti-cancer compounds in various stages of transition from in vitro screening to Phase III clinical trials. His expertise in pharmacogenetics in oncology clinical trials and biomarker endpoints in Phase l/ll anti-cancer agents underscores his superb background to lead the WCI and its scientific programs and shared core resources in this pursuit of NCI designation as a cancer center. In his role as Director of the Winship Cancer Institute, Dr. Leyland-Jones provides overall leadership of the WCI, its scientific programs, its shared core resources, its organization, and its administration. Dr. Leyland-Jones represents the WCI on strategic planning and leadership committees within the Woodruff Health Sciences Center and on the School of Medicine's Council of Chairs. The Authority of the Director is described in considerable detail in the previous section. Dr. Leyland-Jones controls the space, facilities, allocation of fundraising, budget, and other resources of the Winship Cancer Institute. Jointly with individual Department Chairs, he has the ability to recruit new faculty to Emory University, and with the Membership Committee he oversees membership in the WCI. As Director of a matrix Center, Dr. Leyland- Jones interacts closely with other Deans and Department Chairs in the Schools of Medicine, Nursing, and Public Health in the Woodruff Health Sciences Center and in Emory College. He also represents the WCI in collaborations with our community partners, including the American Cancer Society, CDC, Georgia Cancer Coalition, Georgia Research Alliance, Georgia Institute for Technology, Morehouse School of Medicine, GA-CORE, and other institutions throughout Georgia. Dr. Leyland-Jones provides the interface with the National Cancer Institute, with the national and local media, and with patient advocacy organizations and foundations. Dr. Leyland-Jones is committed full-time to his role as WCI Director and as Principal Investigator for the CCSG, but only 25% of his effort is supported by the CCSG budget. He will provide senior leadership, oversight, strategic planning, and on-going evaluation of progress towards meeting established goals and objectives during the course of the project period.